CTLA4 and neoplasm: Although immune checkpoint blockade represents a promising approach in oncology exemplified by successful tumour responses observed with PD-1/PD-L1 and anti-CTLA-4 targeted therapies, careful patient selection and monitoring of the treatment response is mandatory due to the possible toxic side effects.